Eckert & Ziegler is strengthening its market position in Spain- First large order for implants
"Spain is one of the largest European markets for brachytherapy products", explains Dr. Edgar Löffler, Executive Board member of the Eckert & Ziegler AG and Managing Director of Eckert & Ziegler Iberia S.L. "We are glad to increase our product presence in Spain and made the right decision to serve the market more effectively by setting up a wholly-owned subsidiary."
The implants for the treatment of prostate cancer are millimeter-sized, weakly radioactive sources which are implanted in the prostate by means of a hollow needle. In contrast to the surgical removal of the prostate, this treatment -being equally effective - causes considerably less incontinence and impotence rates. Prostate cancer is the most frequent cancer for men in Europe with 135,000 new incidences annually.
In combination with special eye applicators, these sources are used to treat eye cancer.
Apart from its German and Spanish locations, Eckert & Ziegler maintains offices in Los Angeles, Atlanta, San Francisco, Prague, Paris, Milan und Chennai (India) and employs more than 350 people.
Press releases you might also be interested in
Weitere Informationen zum Thema "Medizintechnik":
Neue Herausforderungen bei IoT, Security und KI
Im Jahr 2018 werden anspruchsvolle IoT-Anwendungen die Grenzen der Datenverarbeitung weiter verschieben und IT-Sicherheitsforscher verstärkt selbst ins Visier geraten. Außerdem wird man maschinellem Lernen und künstlicher Intelligenz mit weniger Skepsis begegnen.Weiterlesen